

Aspira Pathlab & Diagnostics Limited

(Formerly known as Utkal Soap Products Ltd.)

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086

CIN:L85100MH1973PLC289209

Corporate Office: Plot No. 6, RPT House, Sector 24, Turbhe, Navi Mumbai 400 703

Date: - 28-10-2017

Corporate Service Department The Calcutta Stock Exchange Limited 7, Lyons Range, Kolkata 700 001

To, Head-Listing & Compliance Metropolitan Stock Exchange of India Ltd. (MSEI) Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai - 400 098, India.

Ref: - ASPIRA PATHLAB & DIAGNOSTIC LIMITED (Formerly known as Utkal Soap Production Ltd)

Sub: Outcome of Board Meeting held on 28th October, 2017.

Dear Sir,

The Board of Director at their meeting held on Saturday 28th October, 2017 has discussed & approved the following matters;

Unaudited Financial Result for the quarter ended and half year ended 30th September, 1. 2017 along with Limited Review Report for the quarter ended 30th September, 2017.

2. Approval of Related Party Transaction.

To keep books of accounts/statutory register at situated at Plot No C-232, TTC Industrial Area, MIDC, Navi Mumbai 400705 (Maharashtra) instead of registered office of the Company.

Appointment of Dr. Subhash Salunke as Additional Non-Executive Independent Director 4. of the Company with effect from 28th October, 2017.

To form a committee of Directors for raising further funds as per SEBI (LODR) 5. Regulations.

Kindly note the same.

Thanking you, For ASPIRA PATHLAB & DIAGNOSTIC LIMITED (Formerly known as Utkal Soap Production Ltd)



Pankaj Shah (Managing Director) DIN:- 02836324

Place:- Mumbai Date: - 28.10.2017





19B B B Ganguly Street Room No. 5, 2nd Floor Kolkata – 700012 Phone- 033-40734009 Mobile- 9883093350 e-mail- khetanpk@gmail.com

Annexure V

Limited Review Report on Quarterly Unaudited Financial Result of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Review Report to:

The Board of Directors of Aspira Pathlab & Diagnostics Limited (Formerly known as Utkal Soap Products Limited) Flat No. 2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai - 400086

WHETAN

Dear Sirs,

We have reviewed the accompanying statement of unaudited standalone financial results of Aspira Pathlab & Diagnostics Limited (Formerly known as Utkal Soap Products Limited) for the period 01st July, 2017 to 30th September, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P Khetan & Co

(Pankaj Kumar Khetan) Partner M.No- 066080

Firm Reg. No- 327386E

Place- Kolkata Date- 27.10.2017

Part I Statement of Standalone Audited Results for the Quarter and Year Ended 31/03/2017

(I in Lakhs except per share data)

Aspira Pathlab & Diagnostics Limited
(CIN LB\$100MH197391C289209)

Reg. Office : Flat No. 2, R.O. Shah Bidg., Shraddhanand Road, Opp. Rallway Station, Ghatkopar (W), Mumbol -400086
Statement of Unaudited Financial Result for the ended 30th Septmember 2017

Particulars	3 months ended (30/09/2017)	Preceding 3 months ended (30/06/2017)	Corresponding 3 months ended in the previous year (30/09/2016)	Year to date figures for current period ended (30/09/2017)	Year to date figures for the previous year ended (30/09/2016)	Year to date figures for the previous year ended (31/03/2017)
(Refer Notes Below)						
1. Income from Operations	di					
(a) Net Sales/Income from Operations (Net of excise duty)	97.85	64.52	0	162.35	0	75.87
(b) Other Operating Income	-	0.00	0		0	
Total income from Operations (net)	97.85	64,52	54.5	162.35		75.87
2. Expenses			(d)			
(a) Cost of Materials consumed	31.67	17.08	0	48.76	0.06	14.22
(b) Employee benefits expense	80.90	72.21	35.2	153.12	45.81	161.18
(c)Depreciation and amortisation expense	33.35	26.16	0		2 332	23.85
(d)Rent, rates and taxes	17.77	17.51	13.35	35.28	18.08	69.08
(e)Power and fuel charges	7.59	12.85	0	Turning Committee Committe	0	
(f)Professionnal fees	8.58	22.79	0	31.37	. 0	
(g)Advertising and business promotion					0	
(h)ROC & other statutory filing fees	1.62	4.86	2.71	6.49	7.15	
(i)Processing Fees related to Share Listing /Delisting	29.5	0	1.05		5.05	0
(j)Other expenses(Any item exceeding 10% of the total	15,000	0100				
expenses relating to continuing operations to be shown separately)	21.47	20.16	5.37	41.64	8.00	35.92
Total Expenses	232.46	193.63	57.68	426.09	84.15	356.67
Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(134.61)	(129.11)	(\$7.68)	(263.74)	(84.15)	(280.80)
4. Other income	6.05	4.82	6.77	10.87	13.52	30.22
5. Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(128.55)	(124.29)	(50.91)	(252.87)	(70.63)	(250.58)
6. Finance Costs	19.51	14.43	3.06	33.93	5.09	25.77
7. Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	(148.06)	(138.72)	(53.97)	(286.80)	(75.72)	(276.35)
S. Exceptional Items						
9. Profit / (Loss) from ordinary activities before tax (7 + 8)	[148.06]	(138.72)	(53.97)	(286,80)	(75.72)	(276.35)
10. Tax expense		Samuel S	1	2 330	6 (6.00)	0
11.Net Profit / (Loss) from ordinary activities after tax (9 + 10) 12. Extraordinary Items (net of tax expense)	(148.06)	(138.72)	(53.97)	(286.80)	(75.72)	(276.35)
L1. Net Profit / (Loss) for the period (11 + 12)	(148.06)	(138.72)	(53.97)	[286.80]	(75.72)	(276.35)
14. Share of Profit / Goss) of associates *			-			
15. Minority interest*	- 10			0 8	C .	
16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(148.06)	(138.72)	(53.97)	(286.80)	(75.72)	(276.35)
17. Paid-up equity share capital Face Value of the Share Rs. 10 each)	519.30	519.30	225	519.30	225	519.3
18. Reserve excluding Revaluation Reserves as per balance sheet of	323.30	313.30		313.30		217.7
previous accounting year		- 10				- V
19.1 Earnings Per Share (before extraordinary items)						
of Rs.10/- each) (not annualised):	-			-		
a) Basic	(2.85)	(2.67)	(2,40)	(5.52)	(3.37)	(8.24)
b) Diluted	(2.85)	(2.67)	(2.40)	(5,52)	(3.37)	(8.24)
19.ii Earnings Per Share (after extraordinary items) of Rs. 10/- each) (not annualised):			-			100.00
a) Basic	(2.85)	(2.67)	(2.40)	(5.52)	(3.37)	(8.24)
b) Diluted see accompanying note to the Financial Results	(2.85)	(2.67)	(2.40)	(5.52)	(3.37)	(8.24)

- Note
 1. The above unaudited financial results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 28.10.17
 2. The previous period figures have been regrouped wherever necessary
 3. The Statutory auditors of the Company have carried out a "Limited Review" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
- 4. The Company has adopted Indian Accounting standards (Ind AS) with effect from 01st April, 2017 and accordingly, the above results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013
- 5. The lind AS complant financial result, pertaining to period ended June 30, 2016 have not been subject to limited review to Audit. However, the management has excercised necessary due deligence to ensure that such financial result provide a true and fair view of its affairs.
- 6. The statement does not include and AS compliant result for the preceding Quarter and previous year ended March 31, 2017 as the same is not mandatory as per SEBFs Circular dated 05th July, 2016
- 7. The reconcilation of net profit or loss reported in accordance with GAAP to total comprehensive income in accordance with Ind AS given below

Discription	Carespanding 3 months ended in previous year 30th September 2016 (Refer Note 5)	
Net Profit/(Loss) as per previous GAAp(Indian GAAP)	(53.97)	
IND AS Adjustment : (Less)	0.00	
Net Profit/(Loss) as per ind AS	(53.97)	
Other Comprehensive Income	0	
Total Comprehensive Income for the period	(53.97)	

For and on behalf of the Board For Aspira Pathlab & Diagnostics Limited (Formerly known as Littal Scap Products Ltd.)

Pankaj Shah (Managing Director) DIN:- 02836324 Place: Mumbei Date: 28.10.2017



Statement of Assets and Liabilities for Companies (Other than Banks)

(@ in Lakhs)

Standalone / Consolidated Statement of Assets and Liabilities Particulars	As at 30/09/2017 (Unaudited)	As at 31/03/2017 Audited)	
EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital			
(b) Reserves and surplus	519.30	519.3	
(c) Money received against share warrants	(218.70)	68.	
Sub-total - Shareholders' funds		-	
2. Share application money pending allotment	300.60	587.7	
3. Minority interest *	•		
4. Non-current liabilities		74	
(a) Long-term borrowings			
(b) Deferred tax liabilities (net)	456.28	317.5	
(c) Other long-term liabilities	-		
(d) Long-term provisions	1.51	1.4	
Sub-total - Non-current liabilities			
5. Current liabilities	457.79	318.98	
(a) Short-term borrowings	404.50		
(b) Trade payables	421.92	361.05	
(c)Other current liabilities	30.73	28.68	
(d) Short-term provisions	24.70	184.26	
Sub-total - Current liabilities	1.11 478.47	1.14	
Total -Liabilities	1,236.85	575.13	
ASSETS	1,630.63	1,481.87	
. Non-current assets			
(a) Tangible Assets	742.20		
(b) Intangible Assets	92.45	669.42	
(c) Work in Progress	32,43	105.60	
(c) Non-current investments		24.52	
(d) Deferred tax assets (net)			
(e) Long-term loans and advances	93.76	-	
(f) Other non-current assets	225.00	59.60	
Sub-total - Non-current assets	1,153.41	225.00	
Current assets	2/255.41	1,084.14	
(a) Current investments	74 7		
(b) Inventories	20.18		
(c) Trade receivables	18.55	11.91	
(d) Cash and cash equivalents	22,41	8.70	
(e) Short-term loans and advances	3.99	281.05	
(f) Other current assets	18.31	48.19	
Sub-total - Current assets	83.44	47.87	
Total -Assets	1,236.85	397.72 1,481.86	

*Applicable in the case of consolidated statement of assets and Liabilities

For and on behalf of the Board

For Aspira Pathlab & Diagnostics Limited

(Formerly known as Utkal Soap Products Ltd.)

Pankaj Shah

(Managing Director)

DIN:- 02836324

Place:- Mumbai

Date:- 28.10.2017

PATHLAB & DIAGNOSTIA Mumbai

known as Utkal Soap Prod